Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
00023728
Ministerstvo Zdravotnictví Ceské Republiky - International
PubMed
30392117
DOI
10.1007/s00296-018-4190-2
PII: 10.1007/s00296-018-4190-2
Knihovny.cz E-zdroje
- Klíčová slova
- Biomarkers, Disease activity, S100 proteins, SLE,
- MeSH
- dospělí MeSH
- kalgranulin A krev MeSH
- kalgranulin B krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- protein S100A12 krev MeSH
- proteiny S100 krev MeSH
- průřezové studie MeSH
- S100 kalcium vázající protein A4 krev MeSH
- studie případů a kontrol MeSH
- systémový lupus erythematodes krev MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- kalgranulin A MeSH
- kalgranulin B MeSH
- protein S100A12 MeSH
- proteiny S100 MeSH
- S100 kalcium vázající protein A4 MeSH
- S100A12 protein, human MeSH Prohlížeč
- S100A4 protein, human MeSH Prohlížeč
- S100A8 protein, human MeSH Prohlížeč
- S100A9 protein, human MeSH Prohlížeč
S100 proteins are currently being investigated as potential diagnostic and prognostic biomarkers of several cancers and inflammatory diseases. The aims of this study were to analyse the plasma levels of S100A4, S100A8/9 and S100A12 in patients with incomplete systemic lupus erythematosus (iSLE), in patients with established SLE and in healthy controls (HCs) and to investigate the potential utility of the S100 proteins as diagnostic or activity-specific biomarkers in SLE. Plasma levels were measured by ELISA in a cross-sectional cohort study of 44 patients with SLE, 8 patients with iSLE and 43 HCs. Disease activity was assessed using the SLEDAI-2K. The mean levels of all S100 proteins were significantly higher in SLE patients compared to HCs. In iSLE patients, the levels of S100A4 and S100A12 but not S100A8/9 were also significantly higher compared to HCs. There were no significant differences in S100 levels between the iSLE and SLE patients. Plasma S100 proteins levels effectively discriminated between SLE patients and HCs. The area under the curve (AUC) for S100A4, S100A8/9 and S100A12 plasma levels was 0.989 (95% CI 0.976-1.000), 0.678 (95% CI 0.563-0.792) and 0.807 (95% CI 0.715-0.899), respectively. S100 levels did not differentiate between patients with high and low disease activity. Only the S100A12 levels were significantly associated with SLEDAI-2K and with cSLEDAI-2K. S100 proteins were significantly higher in SLE patients compared HCs and particularly S100A4 could be proposed as a potential diagnostic biomarker for SLE.
Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic
Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic
Zobrazit více v PubMed
Arthritis Rheum. 2003 Oct;48(10):2888-97 PubMed
Arthritis Res Ther. 2017 Oct 24;19(1):242 PubMed
Transl Res. 2012 Apr;159(4):326-42 PubMed
Rheumatology (Oxford). 2014 Aug;53(8):1520-6 PubMed
Int J Rheum Dis. 2012 Oct;15(5):433-44 PubMed
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8 PubMed
J Invest Dermatol. 2010 Jan;130(1):150-60 PubMed
Arthritis Rheum. 1997 Sep;40(9):1725 PubMed
J Clin Invest. 2005 Nov;115(11):3205-16 PubMed
Immunity. 2010 Dec 14;33(6):905-16 PubMed
Biomarkers. 2015 Feb;20(1):47-51 PubMed
Lupus. 2016 Jan;25(1):38-45 PubMed
Scand J Rheumatol. 2016 Jul;45(4):274-81 PubMed
PLoS Pathog. 2009 Oct;5(10):e1000639 PubMed
Nat Rev Cancer. 2015 Feb;15(2):96-109 PubMed
Lancet. 2014 Nov 22;384(9957):1878-1888 PubMed
J Rheumatol. 1998 Feb;25(2):277-84 PubMed
J Pathol. 2002 Mar;196(3):292-9 PubMed
Sci Transl Med. 2011 Mar 9;3(73):73ra20 PubMed
J Leukoc Biol. 2007 Jan;81(1):28-37 PubMed
Proc Natl Acad Sci U S A. 2010 May 25;107(21):9813-8 PubMed
Gene. 1993 Dec 15;135(1-2):229-38 PubMed
Arthritis Rheum. 2006 May;54(5):1543-56 PubMed
Am J Cancer Res. 2014 Mar 01;4(2):89-115 PubMed
Arthritis Res Ther. 2011 Jul 26;13(4):R122 PubMed
Arthritis Rheum. 1996 Aug;39(8):1432-4 PubMed
Curr Mol Med. 2013 Jan;13(1):24-57 PubMed
J Biol Chem. 2001 Jun 22;276(25):22699-708 PubMed
J Mol Med (Berl). 2008 May;86(5):507-22 PubMed
Oncotarget. 2017 May 19;8(42):73219-73239 PubMed
J Infect Dis. 2011 Sep 1;204(5):722-30 PubMed
Arthritis Res Ther. 2011 Apr 14;13(2):R60 PubMed
J Rheumatol. 2009 Oct;36(10):2190-4 PubMed
Am J Physiol. 1997 Oct;273(4):F563-74 PubMed
Cell Res. 2010 Mar;20(3):314-31 PubMed
Cancer Res. 2017 Oct 1;77(19):5360-5373 PubMed
Hippokratia. 2008;12(4):198-204 PubMed
Tumour Biol. 2016 Mar;37(3):2925-32 PubMed
J Immunol. 2011 Jul 1;187(1):538-52 PubMed
Sci Transl Med. 2011 Mar 9;3(73):73ra19 PubMed
Science. 2004 Mar 5;303(5663):1532-5 PubMed
Nat Rev Rheumatol. 2011 Nov 01;7(12):708-17 PubMed
Lupus. 1993 Feb;2(1):47-50 PubMed
Arthritis Rheum. 2004 Dec;50(12):3762-71 PubMed
Rheumatology (Oxford). 2013 Nov;52(11):2048-55 PubMed
Arthritis Res Ther. 2014 Oct 31;16(5):468 PubMed
Arthritis Rheum. 2007 Mar;56(3):779-89 PubMed
Arthritis Rheumatol. 2016 Aug;68(8):1970-80 PubMed
Am J Pathol. 2006 Jun;168(6):1779-92 PubMed
Cancer Res. 2006 May 15;66(10):5173-80 PubMed
J Rheumatol. 2002 Feb;29(2):288-91 PubMed
J Immunol. 2018 May 15;200(10):3364-3371 PubMed
J Cardiothorac Vasc Anesth. 2004 Oct;18(5):645-56 PubMed
J Surg Oncol. 2006 May 1;93(6):498-503 PubMed
J Leukoc Biol. 2007 Jan;81(1):1-5 PubMed
Oncogene. 2013 Dec 5;32(49):5531-40 PubMed
Methods Mol Biol. 2009;517:363-80 PubMed
